Sample | Vmax | Vmax | Apparent Km | Fraction Unbounda | Corrected Km | Clint,u | Clint,u |
---|---|---|---|---|---|---|---|
pmol/min per milligram of protein | pmol/min per picomole of AOX-1 | μM | fu | μM | μl/min per milligram of protein | μl/min per picomole of AOX-1 | |
Carbazeran 4-oxidation | |||||||
Human liver microsomes (without NADPH)b | 187 ± 17 | 14.5 ± 1.3 | 7.2 ± 1.0 | 0.87 ± 0.01 | 6.3 ± 0.9 | 30 ± 1 | 2.32 ± 0.11 |
Human liver microsomes (with NADPH)b | 179 ± 14 | 13.8 ± 1.0 | 7.1 ± 0.5 | 0.87 ± 0.01 | 6.2 ± 0.4 | 29 ± 1 | 2.21 ± 0.04 |
Human liver cytosol | 1290 ± 138 | 20.2 ± 2.2 | 6.3 ± 0.7 | 0.94 ± 0.02 | 5.9 ± 0.6 | 217 ± 5 | 3.41 ± 0.08 |
Human liver S9 fraction (without NADPH) | 671 ± 83 | 12.6 ± 1.6 | 4.9 ± 0.3 | 0.96 ± 0.01 | 4.7 ± 0.3 | 144 ± 19 | 2.61 ± 0.34 |
Human liver S9 fraction (with NADPH) | 682 ± 83 | 12.8 ± 1.6 | 4.9 ± 0.3 | 0.96 ± 0.01 | 4.7 ± 0.3 | 144 ± 10 | 2.61 ± 0.17 |
O6-Benzylguanine 8-oxidation | |||||||
Human liver microsomes (without NADPH)b | N/Ac | N/Ac | N/Ac | 0.99 ± 0.03 | N/Ac | N/Ac | N/Ac |
Human liver microsomes (with NADPH)b | 94 ± 11 | 7.2 ± 0.9 | 43 ± 4 | 0.99 ± 0.03 | 42 ± 4 | 2.3 ± 0.3 | 0.17 ± 0.03 |
Human liver cytosol | 1254 ± 102 | 19.7 ± 1.6 | 70 ± 8 | 1.01 ± 0.02 | 71 ± 8 | 18 ± 2 | 0.28 ± 0.03 |
Human liver S9 fraction (without NADPH) | 445 ± 10 | 8.35 ± 0.19 | 94 ± 3 | 0.96 ± 0.01 | 90 ± 3 | 4.9 ± 0.2 | 0.09 ± 0.003 |
Human liver S9 fraction (with NADPH) | 454 ± 5 | 8.52 ± 0.09 | 85 ± 9 | 0.96 ± 0.01 | 81 ± 8 | 5.7 ± 0.6 | 0.10 ± 0.01 |
↵a fu from 10 μM carbazeran and 200 μM O6-benzylguanine in the respective enzymes (Supplemental Table S3).
↵b Human liver microsomes from Pool 2.
↵c The V vs. [S] plot did not reach plateau and kinetic values could not be determined. Owing to solubility limit, the maximum substrate concentration was 100 μM.